Hodgkin Lymphoma News and Research

RSS

Newly-discovered protein acts as off switch for human immune cells

Mayo Clinic researchers have identified a protein that cancer cells use to shut down the body's immune response, a discovery that could help scientists develop new treatments that make cancer immunotherapies more effective.

3 Aug 2026

Midpregnancy herbicide exposure linked to increased preterm birth risk

Exposure to a widely used herbicide during the middle months of pregnancy may increase the chance of giving birth too early, before 37 weeks, a new study shows.

31 Jul 2026

Midpregnancy herbicide exposure linked to increased risk of preterm birth

Exposure to a widely used herbicide during the middle months of pregnancy may increase the chance of giving birth too early, before 37 weeks, a new study shows.

22 Jul 2026

AACR report highlights unequal burden of cancer in the United States

The American Association for Cancer Research (AACR) today released its Cancer Disparities Progress Report 2026, a comprehensive analysis of the unequal burden of cancer in the United States.

24 Jun 2026

Higher BMI raises risk for 19 cancers as global review expands the obesity-cancer link

A major systematic review and meta-analysis links higher BMI to increased risk of 19 cancer types, including leukemia, non-Hodgkin lymphoma, bladder cancer, and glioma, which were not previously recognized in major consensus reports. The study also reveals regional and sex-based variation in cancer risk, with genetic evidence generally supporting many observational links while highlighting the need for more diverse global cohorts.

17 Jun 2026

Study reframes Hodgkin lymphoma as a cancer of failed cell development

For the first time, Weill Cornell Medicine researchers have demonstrated that Hodgkin lymphoma cancer cells from patient samples are immune cells stuck in an "identity crisis."

24 Apr 2026

Young cancer survivors face double the risk of later cancers

Survivors of cancer in their teen and young adult years are at double the risk of most types of later cancers, according to research from Alberta published in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.251381.

13 Apr 2026

Precision medicine tools offer hope for patients with rare blood cancers

Personalized approaches have dramatically improved outcomes for many patients with non-Hodgkin B-cell lymphomas—blood cancers that arise in immune cells called B cells—yet the same is not true for patients with more rare lymphoma types that originate in immune cells called T cells.

9 Apr 2026

Pirtobrutinib shows superior outcomes compared to common first-line combination treatment for CLL/SLL

In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more favorable safety profile when compared with bendamustine plus rituximab (BR) in patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

10 Dec 2025

Lymphocyte levels help predict outcomes after CAR T-cell therapy in non-Hodgkin lymphoma

Measuring the lymphocytes - white blood cells that fight infection - in a patient's blood can be used to predict outcomes in non-Hodgkin lymphoma patients who receive CAR T-cell therapy, according to research from physicians at Fox Chase Cancer Center and Temple Health.

8 Dec 2025

Evidence grows for pirtobrutinib as a safer and effective alternative for CLL and SLL

Pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, met the primary endpoint for non-inferiority in terms of overall response rate in the first head-to-head comparison with ibrutinib, a covalent BTK inhibitor.

7 Dec 2025

New trial shows major survival gains with epcoritamab added to standard R2 therapy

In a new trial, patients with follicular lymphoma had a significantly higher response to treatment and a nearly 80% reduction in the risk of death or disease progression if they received epcoritamab in addition to the standard second-line regimen versus the standard regimen alone.

7 Dec 2025

New consortium aims to fast-track breakthroughs against follicular lymphoma

Follicular lymphoma (FL) is the second most frequent subtype of non-Hodgkin lymphoma, a cancer of the immune system. Although the disease is typically incurable, many cases progress slowly and do not require immediate treatment.

1 Dec 2025

Novel model expands fertility options for cancer patients

In patients of reproductive age who have cancer, fertility preservation for potential children in the future should be a high priority.

17 Nov 2025

Common chemical tetrachloroethylene may be harmful to the liver

Liver disease is usually caused by one of three factors: alcohol consumption, fat buildup in the liver linked to obesity, diabetes and high cholesterol, or hepatitis B and C.

23 Oct 2025

Rare case of pancreatic Hodgkin lymphoma is often misdiagnosed as pancreatic adenocarcinoma

A new case report was published in Volume 12 of Oncoscience on October 6, 2025, titled "A peculiar case of primary lymphoma of pancreas: A rare presentation of Hodgkin lymphoma."

22 Oct 2025

Combination therapy shows promising results in patients with rare subtype of non-Hodgkin lymphoma

Combining an epigenetic therapy with an anti-PD-1 antibody, which uses the body's natural response to viral infections, showed promising results in patients with relapsed or refractory natural killer/T-cell lymphoma (R/R NKTL), a rare and aggressive cancer with limited treatment options.

15 Oct 2025

Nuclear missile workers are contracting cancer. They blame the bases.

At a memorial service in 2022, veteran Air Force Capt. Monte Watts bumped into a fellow former Minuteman III nuclear missile operator, who told him that she had non-Hodgkin lymphoma.

3 Oct 2025

The 15th AACR cancer progress report highlights scientific advances

The American Association for Cancer Research (AACR) released the 15th edition of its annual Cancer Progress Report. A cornerstone of the AACR's educational and advocacy efforts, this comprehensive report provides the latest statistics on cancer incidence, mortality, and survivorship and highlights how federal investments in basic, translational, and clinical cancer research and cancer-related population sciences have led to impressive scientific advances that are improving health and saving lives.

17 Sep 2025

Immunoglobulin replacement therapy not associated with reduced risk of serious infections in patients with CLL

In patients with chronic lymphocytic leukemia (CLL), regular treatment with immunoglobulin replacement therapy was not associated with a reduced risk of serious infections requiring hospitalization, according to a study published in Blood Advances.

31 Jul 2025